| # | Title | Journal | Year | Citations |
|---|
| 1 | Radiomics: the bridge between medical imaging and personalized medicine | Nature Reviews Clinical Oncology | 2017 | 3,216 |
| 2 | Tumour-associated macrophages as treatment targets in oncology | Nature Reviews Clinical Oncology | 2017 | 2,667 |
| 3 | Delivering nanomedicine to solid tumors | Nature Reviews Clinical Oncology | 2010 | 2,666 |
| 4 | Tumour heterogeneity and resistance to cancer therapies | Nature Reviews Clinical Oncology | 2018 | 2,149 |
| 5 | Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease | Nature Reviews Clinical Oncology | 2016 | 1,938 |
| 6 | EMT, CSCs, and drug resistance: the mechanistic link and clinical implications | Nature Reviews Clinical Oncology | 2017 | 1,865 |
| 7 | Targeting the IL-6/JAK/STAT3 signalling axis in cancer | Nature Reviews Clinical Oncology | 2018 | 1,789 |
| 8 | Chimeric antigen receptor T-cell therapy — assessment and management of toxicities | Nature Reviews Clinical Oncology | 2018 | 1,659 |
| 9 | Clinical development and potential of photothermal and photodynamic therapies for cancer | Nature Reviews Clinical Oncology | 2020 | 1,622 |
| 10 | The immune contexture in cancer prognosis and treatment | Nature Reviews Clinical Oncology | 2017 | 1,590 |
| 11 | Liquid biopsy: monitoring cancer-genetics in the blood | Nature Reviews Clinical Oncology | 2013 | 1,482 |
| 12 | Integrating liquid biopsies into the management of cancer | Nature Reviews Clinical Oncology | 2017 | 1,375 |
| 13 | Molecular therapies and precision medicine for hepatocellular carcinoma | Nature Reviews Clinical Oncology | 2018 | 1,308 |
| 14 | MicroRNAs in body fluids—the mix of hormones and biomarkers | Nature Reviews Clinical Oncology | 2011 | 1,290 |
| 15 | Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance | Nature Reviews Clinical Oncology | 2019 | 1,235 |
| 16 | Broadening horizons: the role of ferroptosis in cancer | Nature Reviews Clinical Oncology | 2021 | 1,216 |
| 17 | Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges | Nature Reviews Clinical Oncology | 2018 | 1,192 |
| 18 | Targeting apoptosis in cancer therapy | Nature Reviews Clinical Oncology | 2020 | 1,192 |
| 19 | Image-guided cancer surgery using near-infrared fluorescence | Nature Reviews Clinical Oncology | 2013 | 1,121 |
| 20 | Cancer immunoediting and resistance to T cell-based immunotherapy | Nature Reviews Clinical Oncology | 2019 | 1,093 |
| 21 | Patient-derived tumour xenografts as models for oncology drug development | Nature Reviews Clinical Oncology | 2012 | 1,091 |
| 22 | Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update | Nature Reviews Clinical Oncology | 2015 | 1,053 |
| 23 | Cholangiocarcinoma — evolving concepts and therapeutic strategies | Nature Reviews Clinical Oncology | 2018 | 1,051 |
| 24 | Cancer metabolism: a therapeutic perspective | Nature Reviews Clinical Oncology | 2017 | 1,028 |
| 25 | Extracellular vesicles in cancer — implications for future improvements in cancer care | Nature Reviews Clinical Oncology | 2018 | 1,020 |
| 26 | Cancer-related fatigue—mechanisms, risk factors, and treatments | Nature Reviews Clinical Oncology | 2014 | 998 |
| 27 | NTRK fusion-positive cancers and TRK inhibitor therapy | Nature Reviews Clinical Oncology | 2018 | 975 |
| 28 | Targeted agents and immunotherapies: optimizing outcomes in melanoma | Nature Reviews Clinical Oncology | 2017 | 945 |
| 29 | Clinical relevance of circulating cell-free microRNAs in cancer | Nature Reviews Clinical Oncology | 2014 | 915 |
| 30 | The future of cancer treatment: immunomodulation, CARs and combination immunotherapy | Nature Reviews Clinical Oncology | 2016 | 909 |
| 31 | Inflammation and cancer: advances and new agents | Nature Reviews Clinical Oncology | 2015 | 901 |
| 32 | Current state of immunotherapy for glioblastoma | Nature Reviews Clinical Oncology | 2018 | 873 |
| 33 | Regulatory T cells in cancer immunosuppression — implications for anticancer therapy | Nature Reviews Clinical Oncology | 2019 | 872 |
| 34 | Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways | Nature Reviews Clinical Oncology | 2011 | 870 |
| 35 | Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination | Nature Reviews Clinical Oncology | 2016 | 831 |
| 36 | EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood | Nature Reviews Clinical Oncology | 2021 | 826 |
| 37 | Artificial intelligence in digital pathology — new tools for diagnosis and precision oncology | Nature Reviews Clinical Oncology | 2019 | 807 |
| 38 | Treating cancer with selective CDK4/6 inhibitors | Nature Reviews Clinical Oncology | 2016 | 806 |
| 39 | Imaging biomarker roadmap for cancer studies | Nature Reviews Clinical Oncology | 2017 | 792 |
| 40 | Oligometastases revisited | Nature Reviews Clinical Oncology | 2011 | 787 |
| 41 | Monitoring immune-checkpoint blockade: response evaluation and biomarker development | Nature Reviews Clinical Oncology | 2017 | 787 |
| 42 | Engineering strategies to overcome the current roadblocks in CAR T cell therapy | Nature Reviews Clinical Oncology | 2020 | 786 |
| 43 | Targeting the PI3K pathway in cancer: are we making headway? | Nature Reviews Clinical Oncology | 2018 | 762 |
| 44 | Radiotherapy and immunotherapy: a beneficial liaison? | Nature Reviews Clinical Oncology | 2017 | 760 |
| 45 | Combination cancer immunotherapies tailored to the tumour microenvironment | Nature Reviews Clinical Oncology | 2016 | 753 |
| 46 | Acquired resistance to TKIs in solid tumours: learning from lung cancer | Nature Reviews Clinical Oncology | 2014 | 740 |
| 47 | Microsatellite instability in colorectal cancer—the stable evidence | Nature Reviews Clinical Oncology | 2010 | 736 |
| 48 | State-of-the-art strategies for targeting the DNA damage response in cancer | Nature Reviews Clinical Oncology | 2019 | 736 |
| 49 | Treatment of HER2-positive breast cancer: current status and future perspectives | Nature Reviews Clinical Oncology | 2012 | 735 |
| 50 | Understanding the mechanisms and treatment options in cancer cachexia | Nature Reviews Clinical Oncology | 2013 | 729 |
